Literature DB >> 28814489

Right ventricular outflow tract stent versus BT shunt palliation in Tetralogy of Fallot.

Daniel Quandt1,2, Bharat Ramchandani1, Gemma Penford1, John Stickley1, Vinay Bhole1, Chetan Mehta1, Timothy Jones1, David James Barron1, Oliver Stumper1.   

Abstract

OBJECTIVE: This study sets out to compare morbidity, mortality and reintervention rates after stenting of the right ventricular outflow tract (RVOT) versus modified Blalock-Taussig shunt (mBTS) for palliation in patients with tetralogy of Fallot (ToF)-type lesions.
METHODS: Retrospective case review study evaluating 101 patients (64 males) with ToF lesions who underwent palliation with either mBTS (n=41) or RVOT stent (n=60) to augment pulmonary blood flow over a 10-year period. Procedure-related morbidity, mortality and reintervention rates were assessed and compared.
RESULTS: Admission rate to paediatric intensive care unit (PICU) was lower in the RVOT stent group (22% vs 100%; p<0.001). Thirty-day mortality in the RVOT stent group was (1/60 (1.7%)) compared with (2/41 (4.9%)) in the mBTS group (p=0.565). Mortality until surgical repair was comparable in both groups (5/60, 8.4%, including three non-cardiac death in the RVOT stent group vs 2/41, 4.9% (p=0.698)). Total hospital length of stay was shorter for the RVOT stent group (median 7 days vs 14 days; p<0.003). Time to surgical repair was shorter in the RVOT stent group (median 232 days, IQR 113-360) compared with the mBTS group (median 428 days, IQR 370-529; p<0.001) due to improved pulmonary arterial growth.
CONCLUSION: RVOT stenting in Fallot-type lesions can be accomplished safely, with lower PICU admission rate, a shorter hospital length of stay and shorter duration of palliation until complete repair compared with mBTS palliation. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  congenital heart disease surgery; interventional cardiology and endovascular procedures; tetralogy of fallot

Mesh:

Year:  2017        PMID: 28814489     DOI: 10.1136/heartjnl-2016-310620

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  6 in total

1.  Right ventricular outflow tract histology post-stenting and in-stent stenosis.

Authors:  Sudesh Prabhu; Siddhant Mehra; Shravan Kanaparthi; Shreesha Shankar Maiya; Sruti Rao
Journal:  Ann Pediatr Cardiol       Date:  2022-08-19

2.  Palliation Strategy to Achieve Complete Repair in Symptomatic Neonates with Tetralogy of Fallot.

Authors:  Mark A Law; Andrew C Glatz; Jennifer C Romano; Paul J Chai; Christopher E Mascio; Christopher J Petit; Courtney E McCracken; Michael S Kelleman; George T Nicholson; Jeffery J Meadows; Jeffrey D Zampi; Shabana Shahanavaz; Sarosh P Batlivala; Joelle Pettus; Amy L Pajk; Kristal M Hock; Bryan H Goldstein; Athar M Qureshi
Journal:  Pediatr Cardiol       Date:  2022-04-05       Impact factor: 1.838

3.  Right ventricular outflow tract stenting during neonatal and infancy periods: A multi-center, retrospective study.

Authors:  İbrahim Cansaran Tanıdır; Mustafa Orhan Bulut; Hacer Kamalı; Erkut Öztürk; İlker Kemal Yücel; Alper Güzeltaş; Türkay Sarıtaş; Abdullah Erdem; Ahmet Çelebi
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2020-07-28       Impact factor: 0.332

Review 4.  Interventional Cardiology for Congenital Heart Disease.

Authors:  Damien Kenny
Journal:  Korean Circ J       Date:  2018-03-29       Impact factor: 3.243

Review 5.  Recent advances in cardiac catheterization for congenital heart disease.

Authors:  Sok-Leng Kang; Lee Benson
Journal:  F1000Res       Date:  2018-03-26

Review 6.  Current outcomes and treatment of tetralogy of Fallot.

Authors:  Jelle P G van der Ven; Eva van den Bosch; Ad J C C Bogers; Willem A Helbing
Journal:  F1000Res       Date:  2019-08-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.